This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

ARCA biopharma Bilan de santé

Santé financière contrôle des critères 6/6

ARCA biopharma possède un total de capitaux propres de $32.6M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $33.8M et de $1.3M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$33.28m
Fonds propres	US$32.57m
Total du passif	US$1.27m
Total des actifs	US$33.84m

Mises à jour récentes de la santé financière

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Jul 15

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Mar 30

Recent updates

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Apr 04

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Sep 24

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

May 03

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Mar 18

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Nov 27

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Jul 15

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Mar 30

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

Dec 15

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

Dec 15

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

Nov 24

ARCA biopharma reports Q3 results

Nov 02

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ABIO ( $33.8M ) dépassent ses passifs à court terme ( $1.3M ).

Passif à long terme: ABIO n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: ABIO est sans dette.

Réduire la dette: ABIO n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ABIO dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ABIO dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 1 % chaque année

This company is no longer active

ARCA biopharma Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Recent updates

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) for approximately $180 million in a reverse merger transaction.

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) in a reverse merger transaction.

New major risk - Share price stability

Arca Biopharma, Inc. Announces Executive Changes

ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024

ARCA biopharma, Inc. Announces Departure of Christopher D. Ozeroff as Senior Vice President and General Counsel

ARCA biopharma, Inc. Appoints James Flynn to Board of Directors

Insufficient new directors

ARCA biopharma, Inc., Annual General Meeting, Dec 15, 2022

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA Biopharma, Inc. Appoints Jacob Ma-Weaver Has Joined Its Board of Directors

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

Insufficient new directors

ARCA biopharma Establishes Special Committee of the Board of Directors

ARCA biopharma, Inc. Announces Results for ASPEN-COVID-19 Phase 2b Clinical Trial

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA biopharma, Inc. Announces Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Senior VP recently bought US$113k worth of stock

ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

ARCA biopharma, Inc. Provides Update on Aspen-Covid-19 Phase 2B Clinical Trial

Chief Accounting Officer & VP of Finance has left the company

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

New 90-day low: US$3.98

New 90-day high: US$4.93

New 90-day high: US$4.55

ARCA biopharma, Inc. Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

ARCA biopharma, Inc. Announces AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

New 90-day low: US$3.81

ARCA biopharma reports Q3 results

New 90-day low: US$4.03

ARCA biopharma, Inc. Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

ARCA biopharma, Inc. Announces Promotion of Debra Marshall to Chief Medical Officer

New 90-day low: US$4.18

ARCA biopharma, Inc. Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

New 90-day low - US$5.34

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines